Data / Research funding / Childhood Leukemia
Childhood Leukemia: 723 NIH awards ($949.2M) to 164 organizations
723 NIH awards ($949.2M) in the NIH spending category Childhood Leukemia, to 164 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 723 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| COG NCTN Year 12 BIQSFP Progress Report | NIH | National Cancer Institute | 2021 to 2025 | $141,250,012 | April 11, 2014 | February 28, 2026 | HAWKINS, DOUGLAS S. | reporter.nih.gov |
| Children's Oncology Group | NIH | National Cancer Institute | 2023 to 2025 | $31,354,180 | March 1, 2023 | February 28, 2026 | ALONZO, TODD A | reporter.nih.gov |
| CCSG - Administrative Supplement - ECIA | NIH | National Cancer Institute | 2021 to 2025 | $22,920,176 | September 1, 1997 | March 31, 2029 | ODUNSI, KUNLE | reporter.nih.gov |
| Children's Oncology Group Pediatric Early Phase Clinical Trial Network | NIH | National Cancer Institute | 2021 to 2024 | $14,041,303 | May 3, 2024 | July 31, 2024 | WEIGEL, BRENDA J. | reporter.nih.gov |
| Characterizing pediatric genomes through an optimized sequencing approach | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $11,335,114 | September 23, 2016 | August 31, 2025 | GRIMWOOD, JANE | reporter.nih.gov |
| Translating genomic discoveries to improved outcomes for high risk acute leukemia | NIH | National Cancer Institute | 2021 to 2025 | $6,239,168 | January 19, 2017 | August 31, 2030 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Identifying the mechanisms of leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $5,032,279 | September 22, 2021 | August 31, 2028 | CRISPINO, JOHN D | reporter.nih.gov |
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $4,603,890 | June 15, 2022 | May 31, 2027 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting | NIH | National Cancer Institute | 2021 to 2025 | $4,594,192 | September 1, 2021 | August 31, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Molecular Pathogenesis of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $4,591,274 | August 13, 2015 | June 30, 2029 | LEY, TIMOTHY J. | reporter.nih.gov |
| Therapeutic Targeting of Human AML Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $4,546,001 | September 8, 2020 | August 31, 2027 | JORDAN, CRAIG T. | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Combining Targeted RIT and Synergistic Novel Agent-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,984,924 | June 1, 2020 | May 31, 2027 | OROZCO, JOHNNIE JOSE | reporter.nih.gov |
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | NIH | National Cancer Institute | 2021 to 2025 | $3,984,664 | July 16, 2018 | January 31, 2027 | BICKEL, KELLIE | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Prevalence and persistence of the ETV6/RUNX1 pre-leukemic clone | NIH | National Cancer Institute | 2023 to 2025 | $3,924,430 | September 1, 2023 | August 31, 2028 | MARCOTTE, ERIN | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $3,657,208 | March 1, 2020 | February 28, 2026 | SUSSMAN, ELYSE S | reporter.nih.gov |
| Michigan Center for Translational Cancer Proteogenomics | NIH | National Cancer Institute | 2022 to 2025 | $3,656,494 | June 6, 2022 | May 31, 2027 | NESVIZHSKII, ALEXEY I | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,601,018 | April 9, 2021 | March 31, 2027 | HSU, KATHARINE C | reporter.nih.gov |
| Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $3,480,276 | August 1, 2025 | July 31, 2029 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer - Administrative Supplement | NIH | National Cancer Institute | 2022 to 2025 | $3,407,172 | July 5, 2022 | June 30, 2027 | PATEL, SUNITA K | reporter.nih.gov |
| Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,350,719 | December 15, 2020 | November 30, 2025 | SHAH, NEIL P | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $3,200,543 | May 1, 2022 | April 30, 2027 | JIN, JIAN | reporter.nih.gov |
| Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation. | NIH | National Cancer Institute | 2021 to 2025 | $3,119,515 | July 1, 2020 | June 30, 2027 | VINCENT, BENJAMIN G | reporter.nih.gov |
| Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) | NIH | National Cancer Institute | 2021 to 2025 | $3,113,868 | July 1, 2021 | June 30, 2027 | CALABRETTA, BRUNO | reporter.nih.gov |
| Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $3,056,754 | April 1, 2021 | March 31, 2027 | DAVIS, KARA LYNN | reporter.nih.gov |
| Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $3,027,488 | April 1, 2021 | June 30, 2026 | TSIRIGOS, ARISTOTELIS | reporter.nih.gov |
| Adhesion GPCR regulation of acute myeloid leukemia stem cells - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $2,988,590 | March 1, 2021 | February 28, 2026 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,961,810 | July 1, 2021 | June 30, 2026 | YANG, JUN J. | reporter.nih.gov |
| Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | NIH | National Cancer Institute | 2022 to 2025 | $2,958,176 | December 15, 2021 | November 30, 2026 | BOUCHARD, ELIZABETH | reporter.nih.gov |
| Backtracking Leukemia-Typical Somatic Alterations in Cord Blood at Single-cell Resolution | NIH | National Cancer Institute | 2021 to 2025 | $2,927,357 | August 1, 2021 | July 31, 2026 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | NIH | National Cancer Institute | 2021 to 2024 | $2,901,922 | May 1, 2020 | April 30, 2025 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| Metabolic control of normal and malignant hematopoiesis | NIH | National Cancer Institute | 2021 to 2025 | $2,869,404 | September 1, 2020 | May 31, 2027 | INTLEKOFER, ANDREW MICHAEL | reporter.nih.gov |
| Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,864,905 | March 24, 2021 | February 28, 2027 | WOLFSON, JULIE ANNA | reporter.nih.gov |
| Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,776,588 | September 16, 2021 | August 31, 2026 | YU, JIYANG | reporter.nih.gov |
| Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,758,516 | July 1, 2022 | June 30, 2027 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Conformal Total Body and Marrow Irradiation for Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,727,228 | September 13, 2011 | December 31, 2025 | HUI, SUSANTA K | reporter.nih.gov |
| Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | NIH | National Cancer Institute | 2022 to 2025 | $2,704,822 | May 1, 2022 | April 30, 2026 | DE SMITH, ADAM | reporter.nih.gov |
| Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML | NIH | National Cancer Institute | 2022 to 2025 | $2,684,963 | February 3, 2022 | January 31, 2027 | BINDRA, RANJIT | reporter.nih.gov |
| Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $2,677,641 | August 1, 2022 | July 31, 2027 | STIEGLITZ, ELLIOT | reporter.nih.gov |
| Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations | NIH | National Cancer Institute | 2022 to 2025 | $2,657,718 | June 15, 2022 | May 31, 2027 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Membrane protein target for leukemia therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,553,914 | September 1, 2020 | July 31, 2027 | KANG, XUNLEI | reporter.nih.gov |
| Selectively Targeting Oncogenic NRAS in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,550,975 | April 1, 2015 | March 31, 2027 | SHANNON, KEVIN M. | reporter.nih.gov |
| Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,544,479 | September 15, 2021 | February 28, 2027 | SAVONA, MICHAEL R | reporter.nih.gov |
| Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias | NIH | National Cancer Institute | 2021 to 2025 | $2,540,823 | April 1, 2021 | March 31, 2027 | JIN, JIAN | reporter.nih.gov |
| Socioeconomic determinants of childhood cancer outcomes in a large contemporary cohort | NIH | National Cancer Institute | 2022 to 2025 | $2,536,169 | February 1, 2022 | January 31, 2027 | MARCOTTE, ERIN | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2022 to 2025 | $2,523,182 | March 1, 2022 | February 28, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Dissecting innate immune signaling in pre-leukemia evolution | NIH | National Cancer Institute | 2022 to 2025 | $2,523,046 | March 4, 2022 | February 28, 2027 | STARCZYNOWSKI, DANIEL | reporter.nih.gov |
| Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,518,197 | July 1, 2020 | June 30, 2025 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,498,906 | September 1, 2021 | August 31, 2027 | MUNDY-BOSSE, BETHANY | reporter.nih.gov |
| Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,488,178 | March 1, 2022 | February 28, 2027 | BACHOVCHIN, DANIEL | reporter.nih.gov |
| Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization | NIH | National Cancer Institute | 2022 to 2025 | $2,477,191 | December 3, 2021 | November 30, 2026 | HUANG, SUMING | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program - Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,458,093 | August 1, 2015 | June 30, 2026 | LOCK, RICHARD B | reporter.nih.gov |
| Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,438,515 | January 5, 2021 | December 31, 2025 | HSU, KATHARINE C | reporter.nih.gov |
| DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | NIH | National Cancer Institute | 2021 to 2025 | $2,407,764 | December 9, 2020 | November 30, 2025 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,401,768 | July 9, 2021 | June 30, 2026 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| The IL-18-IFNγ axis predicts response to immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,399,099 | February 1, 2023 | January 31, 2028 | GUSTAFSON, HEATHER LEIGH HERD | reporter.nih.gov |
| ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2025 | $2,398,924 | August 22, 2016 | July 31, 2027 | KENTSIS, ALEX | reporter.nih.gov |
| ROLE OF RNA SEQUESTRATION IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2025 | $2,398,360 | August 15, 2025 | July 31, 2029 | DI STEFANO, BRUNO | reporter.nih.gov |
| Escape from CAR T surveillance through lineage plasticity | NIH | National Cancer Institute | 2022 to 2025 | $2,388,454 | April 1, 2022 | March 31, 2027 | ERNST, PATRICIA | reporter.nih.gov |
| Cytomegalovirus as an etiologic and clinico-pathogenic factor in childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,371,097 | June 21, 2022 | May 31, 2028 | WIEMELS, JOSEPH LEO | reporter.nih.gov |
| Targeting obesity to improve survival from childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,359,104 | September 14, 2021 | August 31, 2027 | ORGEL, ETAN | reporter.nih.gov |
| Interrogation of the oxidative-stress-induced leukemia program in vivo using metabolic imaging | NIH | National Cancer Institute | 2023 to 2025 | $2,335,453 | July 1, 2023 | June 30, 2028 | KESHARI, KAYVAN R | reporter.nih.gov |
| Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,325,780 | April 20, 2021 | March 31, 2026 | SHLOMCHIK, WARREN D | reporter.nih.gov |
| Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium | NIH | National Cancer Institute | 2022 to 2025 | $2,325,747 | August 22, 2022 | July 31, 2027 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,317,710 | September 19, 2023 | August 31, 2028 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| Improving risk allocation and developing novel therapies for children with T-ALL and T-LL | NIH | National Cancer Institute | 2023 to 2025 | $2,310,556 | May 4, 2015 | January 31, 2028 | TEACHEY, DAVID T. | reporter.nih.gov |
| RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation | NIH | National Cancer Institute | 2022 to 2025 | $2,310,466 | July 1, 2022 | June 30, 2027 | SMITH, CATHERINE CHOY | reporter.nih.gov |
| Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,291,761 | July 15, 2022 | June 30, 2027 | GETZ, KELLY DIRINGER | reporter.nih.gov |
| THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2025 | $2,282,168 | July 1, 2021 | June 30, 2027 | NAKADA, DAISUKE | reporter.nih.gov |
| The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,254,307 | March 1, 2022 | February 28, 2027 | CHEN, JIANJUN | reporter.nih.gov |
| Chronic Health Conditions in Survivors of Down Syndrome-Associated Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,251,638 | June 20, 2022 | May 31, 2028 | GRAMATGES, MARIA MONICA | reporter.nih.gov |
| Development of ASH1L inhibitors for acute leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,243,021 | December 1, 2019 | November 30, 2025 | GREMBECKA, JOLANTA | reporter.nih.gov |
| Targeting FTO to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,229,526 | December 1, 2019 | November 30, 2025 | CHEN, JIANJUN | reporter.nih.gov |
| Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | NIH | National Cancer Institute | 2022 to 2025 | $2,202,507 | March 1, 2022 | January 31, 2027 | ZAKRZEWSKI, JOHANNES | reporter.nih.gov |
| Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome | NIH | National Cancer Institute | 2021 to 2025 | $2,201,529 | April 1, 2021 | March 31, 2027 | CARROLL, WILLIAM L. | reporter.nih.gov |
| AML mutation-guided drugging of DNA repair | NIH | National Cancer Institute | 2021 to 2024 | $2,200,960 | March 1, 2020 | January 31, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | NIH | National Cancer Institute | 2022 to 2024 | $2,178,209 | January 1, 2020 | December 31, 2025 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,173,427 | September 7, 2020 | June 30, 2026 | REYES, TERESA M | reporter.nih.gov |
| Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,173,391 | June 1, 2020 | May 31, 2025 | ABDEL-WAHAB, OMAR | reporter.nih.gov |
| Role of PRC1 in RUNX1-ETO-mediated transcriptional control | NIH | National Cancer Institute | 2021 to 2025 | $2,144,475 | July 5, 2021 | December 31, 2026 | HODGES, EMILY | reporter.nih.gov |
| The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | NIH | National Cancer Institute | 2022 to 2025 | $2,133,556 | January 1, 2022 | December 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Genomics of AML Prognosis | NIH | National Cancer Institute | 2021 to 2025 | $2,130,312 | April 1, 2008 | June 30, 2027 | LAMBA, JATINDER K. | reporter.nih.gov |
| A novel strategy for transcriptional reprogramming of lymphoid leukemia cells | NIH | National Cancer Institute | 2022 to 2025 | $2,123,519 | January 1, 2022 | December 31, 2026 | CALABRETTA, BRUNO | reporter.nih.gov |
| mRNA stability and its impact on hematopoiesis and acute leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,122,727 | January 1, 2022 | December 31, 2026 | AIFANTIS, IANNIS | reporter.nih.gov |
| Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $2,121,560 | August 1, 2023 | July 31, 2028 | VAKOC, CHRISTOPHER | reporter.nih.gov |
| Predicting and Monitoring for Cardiac Toxicity in Pediatric AML | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,120,249 | August 25, 2023 | July 31, 2027 | APLENC, RICHARD | reporter.nih.gov |
| Towards rational design of combination therapeutic targets | NIH | National Cancer Institute | 2021 to 2024 | $2,120,092 | June 1, 2020 | May 31, 2025 | TAN, KAI | reporter.nih.gov |
| PolQ as a novel therapeutic target in AML | NIH | National Cancer Institute | 2021 to 2024 | $2,115,741 | January 17, 2020 | December 31, 2025 | SKORSKI, TOMASZ | reporter.nih.gov |
| Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $2,114,878 | July 19, 2023 | June 30, 2028 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,106,587 | April 1, 2023 | March 31, 2028 | BANSAL, RAVI | reporter.nih.gov |
| Inhibition of Bcl-xL by Targeted Degradation | NIH | National Cancer Institute | 2021 to 2024 | $2,097,141 | April 1, 2020 | March 31, 2026 | ZHENG, GUANGRONG | reporter.nih.gov |
| Novel combination therapy for AML expressing mutant RUNX1 | NIH | National Cancer Institute | 2021 to 2024 | $2,088,671 | September 1, 2021 | August 31, 2025 | DINARDO, COURTNEY | reporter.nih.gov |
| Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations | NIH | National Cancer Institute | 2022 to 2025 | $2,085,711 | February 14, 2022 | January 31, 2027 | PANNUNZIO, NICHOLAS | reporter.nih.gov |
| Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,084,309 | April 1, 2022 | August 31, 2026 | VARADHACHARY, ATUL | reporter.nih.gov |
| Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,954 | September 1, 2016 | August 31, 2023 | LOOK, A. THOMAS | reporter.nih.gov |
| Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,953 | August 9, 2016 | July 31, 2023 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| EPIGENETIC REPROGRAMMING OF T CELL EXHAUSTION TO ENHANCE TUMOR IMMUNOTHERAPY | NIH | National Cancer Institute | 2021 to 2025 | $2,070,977 | March 1, 2020 | March 31, 2030 | YOUNGBLOOD, BENJAMIN ALAN | reporter.nih.gov |
| New control of oncogene activation in T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,064,320 | April 12, 2022 | March 31, 2027 | LIANG, CHENGYU | reporter.nih.gov |
| Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,055,804 | September 1, 2022 | August 31, 2027 | VAN DER PLAS, ELLEN | reporter.nih.gov |
| Novel CART Cells for Treating AML | NIH | National Cancer Institute | 2022 to 2025 | $2,049,319 | June 1, 2022 | May 31, 2027 | HUA, XIANXIN | reporter.nih.gov |
| Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,039,396 | July 1, 2020 | June 30, 2025 | CHEN, WEIQIANG | reporter.nih.gov |
| Spatial Control of Myeloid Differentiation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,038,767 | August 15, 2021 | December 31, 2024 | LUCAS, DANIEL | reporter.nih.gov |
| Characterizing the MSI2 network in leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,029,035 | April 1, 2015 | November 30, 2025 | KHARAS, MICHAEL | reporter.nih.gov |
| Mechanisms of differentiation blockade in CSF3R-mutant AML | NIH | National Cancer Institute | 2021 to 2025 | $2,023,612 | February 5, 2021 | January 31, 2027 | MAXSON, JULIA E | reporter.nih.gov |
| TET2-mediated epitranscriptomic regulation in leukemia microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $2,018,981 | September 21, 2023 | August 31, 2028 | CHEN, JIANJUN | reporter.nih.gov |
| Targeted Small Molecule Inhibitors for Inv(16) Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $2,012,862 | December 1, 2018 | November 30, 2024 | BUSHWELLER, JOHN HACKETT | reporter.nih.gov |
| Central tolerance mechanisms in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,003,674 | June 1, 2011 | June 30, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML | NIH | National Cancer Institute | 2021 to 2025 | $2,002,562 | March 3, 2021 | February 28, 2026 | HUANG, JIAN | reporter.nih.gov |
| Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,001,625 | September 1, 2022 | August 31, 2027 | BLANCO, MARIO ANDRES | reporter.nih.gov |
| Role of HOTTIP/beta-catenin-HOXA9/PRMT1 axis in hematopoietic and leukemic stem cells | NIH | National Cancer Institute | 2022 to 2025 | $2,000,732 | July 1, 2022 | June 30, 2027 | HUANG, SUMING | reporter.nih.gov |
| AI-based AML risk stratification using next generation cytogenomics | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | July 1, 2023 | June 30, 2025 | EACKER, STEPHEN MATTHEW | reporter.nih.gov |
| Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | July 1, 2023 | June 30, 2025 | FEDERATION, ALEXANDER | reporter.nih.gov |
| TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY | NIH | National Cancer Institute | 2021 | $1,999,993 | August 1, 2021 | July 31, 2023 | LEE, GARY | reporter.nih.gov |
| Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,999,703 | September 1, 2024 | August 31, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $1,999,256 | September 14, 2022 | August 31, 2025 | ADAIR, BERNADETTE MCMAHON | reporter.nih.gov |
| Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target? | NIH | National Cancer Institute | 2021 to 2024 | $1,996,349 | April 1, 2020 | March 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Integrated Systems Biology of Pediatric AML | NIH | National Cancer Institute | 2023 to 2025 | $1,995,809 | December 15, 2022 | November 30, 2027 | LAMBA, JATINDER K. | reporter.nih.gov |
| Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | NIH | National Cancer Institute | 2023 to 2025 | $1,994,514 | August 10, 2023 | July 31, 2026 | VERA, JUAN FERNANDO | reporter.nih.gov |
| The role of the cohesin complex in hematopoietic transformation and leukemia maintenance | NIH | National Cancer Institute | 2023 to 2025 | $1,987,941 | September 19, 2023 | August 31, 2028 | VINY, AARON D | reporter.nih.gov |
| Defining epigenetic mechanisms in NPM1c mutant leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,981,710 | April 9, 2021 | March 31, 2027 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis | NIH | National Cancer Institute | 2021 to 2023 | $1,980,668 | July 1, 2019 | June 30, 2025 | BUSHWELLER, JOHN HACKETT | reporter.nih.gov |
| Towards an inclusive genomic risk classification for acute myeloid leukemia (AML) | NIH | National Cancer Institute | 2023 to 2025 | $1,961,587 | September 18, 2023 | July 31, 2028 | EISFELD, ANN-KATHRIN | reporter.nih.gov |
| Large scale single-cell gene rearrangement detection with a microfluidic device | NIH | National Cancer Institute | 2021 to 2025 | $1,921,615 | July 1, 2020 | June 30, 2027 | ZHONG, JOHN | reporter.nih.gov |
| Mechanism of Therapy in high-risk AML | NIH | National Cancer Institute | 2021 to 2024 | $1,909,701 | July 1, 2020 | June 30, 2025 | AZAM, MOHAMMAD | reporter.nih.gov |
| MICROFABRICATED INSTRUMENTATION TO MEASURE SPHINGOLIPID SIGNALING IN HUMAN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2023 | $1,909,270 | May 7, 2019 | April 30, 2025 | ALLBRITTON, NANCY L. | reporter.nih.gov |
| Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,909,233 | September 3, 2021 | August 31, 2025 | METAYER, CATHERINE | reporter.nih.gov |
| The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,908,225 | December 7, 2020 | November 30, 2026 | LIU, SHUJUN | reporter.nih.gov |
| Regulation of FLT3 Signaling in Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,897,988 | September 1, 2023 | August 31, 2028 | TONG, WEI | reporter.nih.gov |
| A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,882,395 | April 21, 2023 | March 31, 2028 | BROWN, AUSTIN L | reporter.nih.gov |
| Targeting Menin in Acute Leukemia with Upregulated HOX Genes | NIH | National Cancer Institute | 2023 to 2025 | $1,868,714 | May 1, 2023 | April 30, 2028 | GREMBECKA, JOLANTA | reporter.nih.gov |
| Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,860,326 | April 1, 2023 | March 31, 2028 | SIMPSON, RICHARD J | reporter.nih.gov |
| Molecular Mechanism of Leukemogenesis involving AML1-ETO | NIH | National Cancer Institute | 2021 to 2025 | $1,849,687 | July 16, 2004 | March 31, 2027 | ZHANG, DONG-ER | reporter.nih.gov |
| An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $1,843,835 | July 1, 2022 | June 30, 2028 | RAGHUBAR, KIMBERLY PAULINE | reporter.nih.gov |
| Targeting PRC1 in leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,843,693 | September 1, 2023 | August 31, 2028 | CIERPICKI, TOMASZ | reporter.nih.gov |
| METABOLIC REGULATION IN LEUKEMIA-INITIATING CELLS | NIH | National Cancer Institute | 2021 to 2024 | $1,806,031 | April 1, 2015 | June 30, 2025 | NAKADA, DAISUKE | reporter.nih.gov |
| Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,799,538 | July 17, 2019 | June 30, 2025 | SACKSTEIN, ROBERT | reporter.nih.gov |
| Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,797,355 | July 21, 2023 | June 30, 2028 | VASU, SUMITHIRA | reporter.nih.gov |
| Targeting GSK3B in refractory B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,794,818 | July 19, 2023 | June 30, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias | NIH | National Cancer Institute | 2021 to 2025 | $1,785,830 | July 1, 2021 | June 30, 2026 | KAUFMANN, SCOTT H | reporter.nih.gov |
| NextGen - CHOP | NIH | National Cancer Institute | 2022 to 2025 | $1,775,451 | June 1, 2025 | May 31, 2026 | MARIS, JOHN M | reporter.nih.gov |
| Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,769,974 | June 1, 2021 | May 31, 2027 | ALACHKAR, HOUDA | reporter.nih.gov |
| Molecular Pathogenesis of AF10-Rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $1,767,803 | April 12, 2022 | March 31, 2027 | DESHPANDE, ANIRUDDHA J. | reporter.nih.gov |
| Targeting Microenvironmental Signals in Myeloid Malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,754,424 | July 1, 2022 | June 30, 2027 | BAJAJ, JEEVISHA | reporter.nih.gov |
| Overcoming Leukemia Chemoresistance in the Central Nervous System | NIH | National Cancer Institute | 2021 to 2025 | $1,736,717 | March 4, 2020 | March 31, 2027 | GORDON, PETER M | reporter.nih.gov |
| Discovery of small molecules targeting the histone acetylation reader ENL | NIH | National Cancer Institute | 2021 to 2024 | $1,734,163 | December 15, 2020 | December 1, 2025 | WEN, HONG | reporter.nih.gov |
| Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | NIH | National Cancer Institute | 2023 to 2024 | $1,730,616 | September 9, 2020 | July 31, 2025 | DESAI, AVINASH | reporter.nih.gov |
| Mechanisms of venetoclax combination activity in acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,729,672 | June 2, 2021 | May 31, 2026 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,719,656 | December 10, 2021 | November 30, 2026 | SONG, YONGCHENG | reporter.nih.gov |
| Metabolic adaptation in lymphoid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,709,232 | December 1, 2019 | November 30, 2025 | ZHANG, JI | reporter.nih.gov |
| Novel functions of CDK6 in T-cell leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $1,701,837 | August 1, 2021 | July 31, 2026 | WANG, HAIZHEN | reporter.nih.gov |
| Role of Protein Arginine Methyltransferase 9 in Acute Myeloid Leukemia Maintenance | NIH | National Cancer Institute | 2021 to 2024 | $1,695,047 | March 1, 2020 | February 28, 2025 | LI, LING | reporter.nih.gov |
| Development of AMPK Inhibitors for the treatment of leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,690,278 | July 1, 2021 | June 30, 2027 | REIGAN, PHILIP | reporter.nih.gov |
| The role of inflammation in the regulation of immune response in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,687,418 | July 6, 2023 | June 30, 2028 | AIFANTIS, IANNIS | reporter.nih.gov |
| Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,684,284 | December 1, 2023 | February 16, 2025 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,682,310 | March 1, 2023 | February 29, 2028 | SYKES, STEPHEN MATTHEW | reporter.nih.gov |
| Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,672,253 | August 1, 2022 | July 31, 2027 | MA, XIAOTU | reporter.nih.gov |
| Enhancer Dysregulation in AML | NIH | National Cancer Institute | 2021 to 2023 | $1,657,025 | March 1, 2019 | February 28, 2025 | DOU, YALI | reporter.nih.gov |
| Molecular epidemiology of acute lymphoblastic leukemia in children with Down syndrome | NIH | National Cancer Institute | 2023 to 2024 | $1,645,759 | August 3, 2020 | July 31, 2025 | RABIN, KAREN R | reporter.nih.gov |
| Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study | NIH | National Cancer Institute | 2021 to 2024 | $1,638,139 | August 1, 2020 | July 31, 2025 | SPECTOR, LOGAN G. | reporter.nih.gov |
| BET bromodomain inhibition as targeted therapy in acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,634,470 | April 1, 2013 | November 30, 2024 | VAKOC, CHRISTOPHER | reporter.nih.gov |
| Cellular and Molecular mechanisms of ATRA inhibition of osteoblast-induced MDS development | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,628,178 | February 15, 2021 | November 30, 2025 | KOUSTENI, STAVROULA | reporter.nih.gov |
| Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,620,456 | April 1, 2022 | January 31, 2027 | WOOD, KRIS C. | reporter.nih.gov |
| Identifying host factors that block engraftment and progression of transmissible cancer as a model of AML | NIH | National Cancer Institute | 2022 to 2025 | $1,617,947 | January 1, 2022 | December 31, 2026 | METZGER, MICHAEL JEFFREY | reporter.nih.gov |
| Novel targeted therapy to reduce health disparities in pediatric leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,596,016 | June 1, 2023 | May 31, 2028 | DOVAT, SINISA | reporter.nih.gov |
| Exploring microRNA degradation in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,594,435 | July 1, 2023 | June 30, 2028 | XIE, MINGYI | reporter.nih.gov |
| Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,571,361 | August 1, 2004 | June 30, 2027 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| BCL11B activation as an approach for enhancing the efficacy of immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,566,114 | February 11, 2021 | July 1, 2024 | PAREKH, CHINTAN | reporter.nih.gov |
| Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,563,164 | December 20, 2019 | November 30, 2025 | KIEM, HANS-PETER | reporter.nih.gov |
| Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $1,562,631 | April 1, 2020 | March 31, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Heat Shock Transcription Factor 1 Specifically Regulates AML Stem Cell Self-Renewal | NIH | National Cancer Institute | 2021 to 2024 | $1,558,730 | December 15, 2019 | May 31, 2025 | ZHAO, CHEN | reporter.nih.gov |
| GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer | NIH | National Cancer Institute | 2022 to 2024 | $1,551,911 | September 21, 2022 | August 31, 2025 | VOLCHENBOUM, SAMUEL | reporter.nih.gov |
| Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL | NIH | National Cancer Institute | 2021 to 2024 | $1,543,188 | August 12, 2014 | February 28, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,530,763 | July 15, 2019 | June 30, 2025 | SMITHGALL, THOMAS E. | reporter.nih.gov |
| Dependency of AML on CARM1 activity | NIH | National Cancer Institute | 2021 to 2024 | $1,525,290 | July 1, 2020 | June 30, 2026 | NIMER, STEPHEN D. | reporter.nih.gov |
| Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | NIH | National Cancer Institute | 2023 to 2025 | $1,520,378 | March 9, 2023 | February 29, 2028 | CARLESSO, NADIA | reporter.nih.gov |
| Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence | NIH | National Cancer Institute | 2022 to 2025 | $1,507,401 | July 1, 2015 | December 31, 2026 | ROOSE, JEROEN | reporter.nih.gov |
| Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,506,076 | June 1, 2019 | May 31, 2025 | CHIANG, MARK Y | reporter.nih.gov |
| Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,503,951 | July 13, 2023 | June 30, 2028 | BRAUN, THEODORE PAUL | reporter.nih.gov |
| Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,502,277 | July 3, 2024 | June 30, 2029 | GENOVESE, PIETRO | reporter.nih.gov |
| The Role of the CBFB-MYH11 Complex in Leukemia Maintenance | NIH | National Cancer Institute | 2021 to 2024 | $1,488,680 | April 1, 2020 | March 31, 2026 | HYDE, RICIA KATHERINE | reporter.nih.gov |
| Promoting immunity against acute myeloid leukemia through Fc effector-optimized antibody inhibitory of MICA/B shedding | NIH | National Cancer Institute | 2023 to 2025 | $1,481,935 | February 6, 2023 | November 30, 2027 | FERRARI DE ANDRADE, LUCAS | reporter.nih.gov |
| Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner | NIH | National Cancer Institute | 2023 to 2025 | $1,480,550 | January 1, 2022 | December 31, 2026 | WANG, G GREG | reporter.nih.gov |
| Investigating novel synthetic lethal epigenetic interactions in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,477,105 | December 13, 2021 | November 30, 2026 | SHI, JUNWEI | reporter.nih.gov |
| Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL | NIH | National Cancer Institute | 2022 to 2025 | $1,475,782 | November 10, 2021 | June 30, 2026 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Regulation of Protein Synthesis in Leukemia Stem Cells | NIH | National Cancer Institute | 2023 to 2025 | $1,469,725 | September 21, 2023 | August 31, 2028 | CHUNG, STEPHEN SHIU-WAH | reporter.nih.gov |
| Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome | NIH | National Cancer Institute | 2021 to 2023 | $1,456,346 | August 1, 2019 | July 31, 2025 | SAVIC, DANIEL | reporter.nih.gov |
| Targeted Inhibition in Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,448,596 | July 8, 2020 | June 30, 2025 | NASSAR, NICOLAS | reporter.nih.gov |
| A compass for those with relapsed leukemia after transplant | NIH | National Cancer Institute | 2024 to 2025 | $1,435,661 | June 1, 2024 | May 31, 2026 | FURLAN, SCOTT NICHOLAS | reporter.nih.gov |
| Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,435,114 | December 8, 2023 | November 30, 2028 | LI, LING | reporter.nih.gov |
| MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication | NIH | National Cancer Institute | 2024 to 2025 | $1,434,826 | April 1, 2024 | March 31, 2029 | BOUCHARD, ELIZABETH | reporter.nih.gov |
| Human Acute Myeloid Leukemia Stem Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,433,586 | July 7, 2020 | June 30, 2025 | MAJETI, RAVINDRA | reporter.nih.gov |
| JAK/STAT signaling in the pathogenesis of DNMT3A mutant T-ALL | NIH | National Cancer Institute | 2021 to 2024 | $1,431,107 | December 12, 2019 | November 30, 2025 | CHALLEN, GRANT ANTHONY | reporter.nih.gov |
| Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,425,147 | December 1, 2021 | November 30, 2026 | XU, JIAN | reporter.nih.gov |
| Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,420,921 | April 1, 2023 | March 31, 2028 | BETTS, BRIAN C | reporter.nih.gov |
| Dysregulated genome architecture in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,406,237 | February 1, 2022 | January 31, 2027 | SPENCER, DAVID H | reporter.nih.gov |
| Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,404,992 | June 12, 2024 | May 31, 2027 | ALTMAN, GARY G. | reporter.nih.gov |
| Integration of epigenetic and non-coding RNA mechanism in leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,402,421 | July 1, 2023 | June 30, 2025 | MEYER, SARA E | reporter.nih.gov |
| Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis | NIH | National Cancer Institute | 2021 to 2024 | $1,400,663 | January 6, 2020 | December 31, 2025 | SIPKINS, DOROTHY A | reporter.nih.gov |
| Mechanistic Study of Methotrexate-Induced Oxidative Distress in Neurons and the CSF | NIH | National Cancer Institute | 2024 to 2025 | $1,400,576 | June 1, 2024 | May 31, 2026 | KANAREK, NAAMA | reporter.nih.gov |
| The role of YTHDC1 in normal and malignant hematopoiesis | NIH | National Cancer Institute | 2022 to 2025 | $1,397,380 | May 10, 2022 | July 28, 2025 | QIAN, ZHIJIAN | reporter.nih.gov |
| Genetic pleiotropy across pediatric cancers, and cancer-related outcomes | NIH | National Cancer Institute | 2024 to 2025 | $1,395,864 | May 16, 2024 | April 30, 2029 | WANG, ZHAOMING | reporter.nih.gov |
| Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,394,210 | September 19, 2023 | August 31, 2028 | HUFF, CHAD DANIEL | reporter.nih.gov |
| 3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors | NIH | National Cancer Institute | 2022 to 2024 | $1,382,980 | May 10, 2022 | December 31, 2024 | SINTIM, HERMAN O | reporter.nih.gov |
| Targeting PTPN11 dependent Hematologic Malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,377,397 | December 1, 2019 | November 30, 2024 | CHANG, BILL H | reporter.nih.gov |
| The Phosphatase PRL3 as a MYC Target and Pro-Survival Oncogene in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,375,452 | April 1, 2023 | March 31, 2026 | BLACKBURN, JESSICA S. | reporter.nih.gov |
| Pathways of Immune Evasion in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,374,087 | March 18, 2022 | February 28, 2027 | LIND, EVAN FERGUSON | reporter.nih.gov |
| Proteogenomic Translational Research Center for Clinical Proteomic | NIH | National Cancer Institute | 2021 | $1,369,292 | June 8, 2017 | May 31, 2023 | RODLAND, KARIN D | reporter.nih.gov |
| MEF2D-Mediated Transcriptional Control of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,368,138 | December 20, 2021 | November 30, 2026 | LU, RUI | reporter.nih.gov |
| Variant to Function Mapping of B-ALL Risk Loci | NIH | National Cancer Institute | 2024 to 2025 | $1,364,988 | July 15, 2024 | June 30, 2029 | SANKARAN, VIJAY GANESH | reporter.nih.gov |
| Defining and targeting asparaginase resistance mechanisms in high-risk acute leukemias | NIH | National Cancer Institute | 2021 to 2024 | $1,364,916 | September 1, 2015 | July 21, 2024 | GUTIERREZ, ALEJANDRO | reporter.nih.gov |
| Role of heat shock transcription factors (HSFs) in hematological malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,364,627 | January 15, 2023 | December 31, 2027 | MIVECHI, NAHID F | reporter.nih.gov |
| The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML | NIH | National Cancer Institute | 2021 to 2023 | $1,361,506 | February 1, 2019 | January 31, 2024 | CHEN, JIANJUN | reporter.nih.gov |
| Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | NIH | National Cancer Institute | 2021 to 2024 | $1,355,619 | August 24, 2021 | August 31, 2024 | KNOECHEL, BIRGIT | reporter.nih.gov |
| Dissecting stress granule dependencies in leukemia stem cells | NIH | National Cancer Institute | 2023 to 2025 | $1,353,928 | July 1, 2023 | June 30, 2028 | YEO, EUGENE WEI-MING | reporter.nih.gov |
| Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML) | NIH | National Cancer Institute | 2023 to 2025 | $1,351,576 | July 1, 2023 | June 30, 2028 | SMITH, CATHERINE CHOY | reporter.nih.gov |
| Targeting NSD1 in leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,348,881 | December 1, 2018 | November 30, 2024 | CIERPICKI, TOMASZ | reporter.nih.gov |
| Cellular and functional impact of SAMD9L mutations on hematopoiesis and myelodysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,346,250 | January 1, 2019 | December 31, 2024 | KLCO, JEFFERY M | reporter.nih.gov |
| ETS1-dependent combinatorial control of oncogenic transcription in Notch-activated T-ALL | NIH | National Cancer Institute | 2023 to 2025 | $1,345,736 | June 1, 2023 | May 31, 2028 | CHIANG, MARK Y | reporter.nih.gov |
| Epigenetic deregulation of osteoblasts promotes age related clonality in hematopoietic cells | NIH | National Institute on Aging | 2024 to 2025 | $1,335,986 | August 15, 2024 | April 30, 2029 | KOUSTENI, STAVROULA | reporter.nih.gov |
| The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $1,328,517 | December 7, 2020 | August 28, 2022 | LIU, SHUJUN | reporter.nih.gov |
| Clonal analysis of cancer by mitochondrial DNA barcoding | NIH | National Cancer Institute | 2023 to 2025 | $1,327,254 | May 11, 2023 | April 30, 2026 | VAN GALEN, PETER | reporter.nih.gov |
| A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,320,612 | May 15, 2024 | April 30, 2029 | SCHEIDT, KARL A | reporter.nih.gov |
| Mechanisms of Leukemogenesis in AMKL | NIH | National Cancer Institute | 2023 to 2024 | $1,319,887 | May 1, 2020 | April 30, 2026 | KRAUSE, DIANE S | reporter.nih.gov |
| Cross-species development and credentialing of pediatric AML models | NIH | National Cancer Institute | 2024 to 2025 | $1,315,008 | December 15, 2023 | November 30, 2028 | MAGEE, JEFFREY ALAN | reporter.nih.gov |
| Role of BAZ2A in MLL-r leukemia and therapeutic response | NIH | National Cancer Institute | 2021 to 2023 | $1,311,299 | April 1, 2019 | March 31, 2024 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Identification of therapeutic targets for leukemia stem cells in AML-iPSC models | NIH | National Cancer Institute | 2021 to 2022 | $1,306,690 | March 1, 2018 | February 28, 2023 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning | NIH | National Cancer Institute | 2024 to 2025 | $1,302,677 | September 9, 2024 | August 31, 2029 | MANALIS, SCOTT R | reporter.nih.gov |
| Characterizing vitamin B6 pathway dependency in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,295,641 | January 5, 2023 | December 31, 2027 | ZHANG, LINGBO | reporter.nih.gov |
| Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,292,812 | July 15, 2023 | June 30, 2028 | SWAMINATHAN, SRIVIDYA | reporter.nih.gov |
| Neurostimulation in Adult Survivors of Childhood Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $1,282,490 | May 1, 2019 | April 30, 2025 | BRINKMAN, TARA M | reporter.nih.gov |
| Targeting the menin-MLL1 complex for new therapeutics | NIH | National Cancer Institute | 2021 to 2022 | $1,280,898 | April 4, 2018 | March 31, 2024 | WANG, SHAOMENG | reporter.nih.gov |
| DLK1 as a novel target for Down syndrome myeloid leukemia | NIH | National Cancer Institute | 2025 | $1,273,073 | September 3, 2025 | August 31, 2027 | GOPALAKRISHNAPILLAI, ANILKUMAR | reporter.nih.gov |
| Selective targeting of TAF1 function in acute myeloid leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,271,248 | February 16, 2024 | January 31, 2029 | SCHONBRUNN, ERNST | reporter.nih.gov |
| Childhood Hematological Malignancies Training Program | NIH | National Cancer Institute | 2021 to 2025 | $1,268,552 | August 8, 2019 | July 31, 2029 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| Role of TET2 mutations in malignant transformation and acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2022 | $1,265,588 | February 7, 2013 | May 31, 2025 | LEVINE, ROSS L | reporter.nih.gov |
| Molecular and cellular mechanisms of neuronal damage caused by anticancer therapies | NIH | National Cancer Institute | 2024 to 2025 | $1,261,134 | March 1, 2024 | February 28, 2029 | DUMAN, JOSEPH G | reporter.nih.gov |
| Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,260,668 | February 1, 2023 | January 31, 2028 | BALTHASAR, JOSEPH P | reporter.nih.gov |
| Targeted therapy for t(8;21)+ AML | NIH | National Cancer Institute | 2021 to 2025 | $1,252,041 | September 17, 2012 | February 28, 2029 | NIMER, STEPHEN D. | reporter.nih.gov |
| Targeting leukemic stem cells in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,245,370 | January 1, 2023 | December 31, 2027 | QU, CHENG-KUI | reporter.nih.gov |
| Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML. | NIH | National Cancer Institute | 2021 to 2025 | $1,239,925 | August 1, 2021 | July 31, 2026 | HUANG, BENJAMIN | reporter.nih.gov |
| The role of ATM in the suppression of lymphoid malignancy | NIH | National Cancer Institute | 2021 to 2025 | $1,239,512 | March 1, 2011 | July 31, 2029 | ZHA, SHAN | reporter.nih.gov |
| UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,228,160 | September 22, 2023 | August 31, 2028 | KLCO, JEFFERY M | reporter.nih.gov |
| Characterization of Diverse Pediatric Cancers in LMIC Using Low-Cost Nanopore Sequencing | NIH | National Cancer Institute | 2024 to 2025 | $1,226,342 | July 15, 2024 | June 30, 2026 | WANG, JEREMY R | reporter.nih.gov |
| Therapeutic value and mechanistic action of PSPC1 in AML | NIH | National Cancer Institute | 2024 to 2025 | $1,215,123 | June 1, 2024 | May 31, 2026 | XU, MINGJIANG | reporter.nih.gov |
| AKR1C3 Inhibitors as Chemotherapeutic Potentiators | NIH | National Cancer Institute | 2021 to 2023 | $1,214,980 | January 1, 2019 | December 31, 2024 | TRIPPIER, PAUL | reporter.nih.gov |
| The Novel Role and Mechanism of RBM33 in Leukemogenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,212,132 | May 17, 2022 | July 28, 2025 | QIAN, ZHIJIAN | reporter.nih.gov |
| Novel analysis of association between microbiome and treatment infection in AML | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,206,148 | September 23, 2019 | August 31, 2025 | HU, JIANHUA | reporter.nih.gov |
| Identification of novel biomarkers and therapeutic strategies in chemobrain. | NIH | National Cancer Institute | 2024 to 2025 | $1,187,289 | June 26, 2024 | May 31, 2026 | JANG, MI-HYEON | reporter.nih.gov |
| State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,181,920 | September 19, 2024 | August 31, 2029 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| Biologic Mechanisms and Dosing of Active Music Engagement to Manage Acute Treatment Distress and Improve Health Outcomes in Young Children with Acute Lymphoblastic Leukemia and Parents | NIH | National Institute of Nursing Research | 2021 to 2024 | $1,181,154 | September 19, 2019 | October 31, 2025 | ROBB, SHERI L | reporter.nih.gov |
| Hyperglycemia mediated myeloproliferative disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,165,622 | April 1, 2019 | March 31, 2024 | KAPUR, REUBEN | reporter.nih.gov |
| Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients with Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,157,135 | July 19, 2024 | June 30, 2029 | EL-JAWAHRI, AREEJ | reporter.nih.gov |
| Molecular Mechanism of TET-mediated Gene Regulation | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,149,787 | September 1, 2023 | July 31, 2028 | LIO, JERRY CHAN-WANG | reporter.nih.gov |
| Support For Infrastructure of Childhood Leukemia Environmental Research | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,140,602 | September 30, 2017 | January 31, 2028 | METAYER, CATHERINE | reporter.nih.gov |
| The histone demethylase JMJD1C in human Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,135,709 | May 16, 2019 | April 30, 2024 | ZHU, NAN | reporter.nih.gov |
| Mechanism and therapeutic opportunities of targeting the Tudor domain | NIH | National Cancer Institute | 2023 to 2025 | $1,132,200 | December 1, 2022 | February 16, 2025 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Molecular analysis of ASH1L | NIH | National Cancer Institute | 2021 to 2025 | $1,125,237 | July 1, 2020 | June 30, 2027 | KUTATELADZE, TATIANA G | reporter.nih.gov |
| The Role of MYC Mutations in acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,125,165 | July 13, 2021 | June 30, 2026 | FERRARO, FRANCESCA | reporter.nih.gov |
| Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer | NIH | National Cancer Institute | 2022 to 2023 | $1,123,266 | January 1, 2022 | July 31, 2023 | WANG, G GREG | reporter.nih.gov |
| USP18 in Cancer Development | NIH | National Cancer Institute | 2021 to 2023 | $1,120,018 | April 1, 2019 | March 31, 2025 | ZHANG, DONG-ER | reporter.nih.gov |
| Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,114,912 | January 1, 2019 | December 31, 2024 | FARRAR, MICHAEL ARCHIBALD | reporter.nih.gov |
| Role of Shp2 in FLT3-ITD induced leukemogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,107,227 | April 1, 2011 | January 31, 2025 | KAPUR, REUBEN | reporter.nih.gov |
| Acquisition of OrbiTrap Eclipse w/FAIMS mass spectrometer | NIH | Office of the Director, National Institutes of Health | 2022 | $1,100,563 | July 1, 2022 | June 30, 2023 | GAFKEN, PHILIP R | reporter.nih.gov |
| Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $1,094,957 | December 10, 2018 | November 30, 2025 | PAGUIRIGAN, AMY | reporter.nih.gov |
| Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML | NIH | National Cancer Institute | 2024 to 2025 | $1,092,328 | December 1, 2023 | November 30, 2028 | ZHOU, MUXIANG | reporter.nih.gov |
| Targeting Novel Pathways in JMML | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,084,832 | January 15, 2019 | December 31, 2023 | KAPUR, REUBEN | reporter.nih.gov |
| Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,082,098 | June 1, 2024 | May 31, 2029 | RYEOM, SANDRA | reporter.nih.gov |
| Structural surfaceomics to probe conformation-selective immunotherapy targets | NIH | National Cancer Institute | 2024 to 2025 | $1,081,632 | August 1, 2024 | July 31, 2029 | WIITA, ARUN P. | reporter.nih.gov |
| Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform | NIH | National Cancer Institute | 2025 | $1,073,736 | July 8, 2025 | June 30, 2027 | MAULDIN, FRANK WILLIAM | reporter.nih.gov |
| Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML) | NIH | National Cancer Institute | 2021 | $1,070,000 | August 1, 2020 | July 31, 2022 | LIAO, CHARLENE | reporter.nih.gov |
| Assessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,056,740 | July 22, 2022 | June 30, 2026 | XIAO, WENBIN | reporter.nih.gov |
| Mechanisms of regulation by RNA in acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $1,042,185 | August 1, 2015 | July 31, 2023 | TENEN, DANIEL G | reporter.nih.gov |
| Penalized mixture cure models for identifying genomic features associated with outcome in acute myeloid leukemia | NIH | National Library of Medicine | 2022 to 2025 | $1,035,933 | January 1, 2022 | December 31, 2026 | ARCHER, KELLIE J. | reporter.nih.gov |
| Enhancing TET activity for the treatment of hematological malignancy | NIH | National Cancer Institute | 2023 to 2025 | $1,035,837 | August 1, 2023 | July 31, 2028 | CIMMINO, LUISA | reporter.nih.gov |
| Role of LAM-specific TREM1 in leukemogenesis | NIH | National Cancer Institute | 2024 to 2025 | $1,035,236 | August 9, 2024 | July 31, 2029 | DU, WEI | reporter.nih.gov |
| Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,034,244 | March 1, 2020 | August 31, 2025 | GARCIA, JACQUELINE SUEN | reporter.nih.gov |
| Epigenetic drivers of cancer progression | NIH | National Cancer Institute | 2021 to 2023 | $1,032,037 | May 1, 1991 | June 30, 2025 | FEINBERG, ANDREW P. | reporter.nih.gov |
| Adapting flow cytometry methods for early detection of acute hematologic malignancies in Kenya including the improvement of sample flow processes and technical training of personnel | NIH | National Cancer Institute | 2024 to 2025 | $1,030,249 | July 2, 2024 | June 30, 2029 | VIK, TERRY A | reporter.nih.gov |
| Dissecting and engineering CAR T-cell function for optimized Immunotherapy | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,028,148 | September 1, 2019 | June 30, 2024 | CHEN, WEIQIANG | reporter.nih.gov |
| Targeting High-Risk Lymphoid Neoplasms | NIH | National Cancer Institute | 2021 | $1,021,025 | August 1, 2019 | June 30, 2022 | WEINSTOCK, DAVID MARC | reporter.nih.gov |
| Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies | NIH | National Cancer Institute | 2021 to 2024 | $1,020,180 | July 1, 2021 | June 30, 2025 | CAI, SHENG | reporter.nih.gov |
| NexTGen - STANFORD | NIH | National Cancer Institute | 2022 to 2024 | $1,019,396 | June 1, 2024 | May 31, 2025 | WEISSMAN, IRVING L. | reporter.nih.gov |
| Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies | NIH | National Cancer Institute | 2021 | $1,004,844 | September 1, 2017 | July 31, 2023 | DRUKER, BRIAN J | reporter.nih.gov |
| Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor | NIH | National Cancer Institute | 2021 | $999,998 | June 1, 2020 | May 31, 2024 | HOLTSBERG, FREDERICK WAYNE | reporter.nih.gov |
| NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML | NIH | National Cancer Institute | 2022 to 2025 | $996,192 | September 1, 2022 | June 30, 2027 | RICHARDS, REBECCA MARGARET | reporter.nih.gov |
| Targeting mitochondrial complex I in acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2024 | $991,893 | June 14, 2019 | May 31, 2026 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY | NIH | National Cancer Institute | 2021 to 2024 | $981,752 | August 23, 2019 | July 31, 2025 | JAMES, LINDSEY INGERMAN | reporter.nih.gov |
| Targeting MBNL1-mediated alternative splicing in MLL-fusion leukemia | NIH | National Cancer Institute | 2021 to 2025 | $980,560 | March 25, 2021 | February 28, 2027 | LEE, LYNN HUA | reporter.nih.gov |
| Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $967,500 | September 7, 2018 | August 31, 2023 | ERB, MICHAEL A | reporter.nih.gov |
| Developing a novel therapeutic strategy for overcoming TKI resistance in ALL | NIH | National Cancer Institute | 2021 to 2022 | $965,937 | December 1, 2017 | May 31, 2024 | LI, SHAOGUANG | reporter.nih.gov |
| Molecular pathways and targeted therapies in human leukemia | NIH | National Cancer Institute | 2021 | $960,000 | September 30, 2017 | August 31, 2022 | FERRANDO, ADOLFO A. | reporter.nih.gov |
| A Multiplatform Approach to Develop ENL-Targeting Molecules as Drug Candidates for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $956,566 | June 1, 2024 | May 31, 2026 | LIU, WENSHE RAY | reporter.nih.gov |
| Elucidate the Role of RNA Editing in Acute T-cell Lymphoblastic Leukemia Initiating Cells | NIH | National Cancer Institute | 2024 to 2025 | $952,971 | May 1, 2024 | April 30, 2029 | JIANG, QINGFEI | reporter.nih.gov |
| The histone demethylase JMJD1C in human Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $950,625 | May 1, 2024 | April 30, 2026 | ZHU, NAN | reporter.nih.gov |
| IDP mediated transcriptional stabilization as a cause of AML | NIH | National Cancer Institute | 2022 to 2025 | $945,544 | April 1, 2022 | March 31, 2027 | BERNT, KATHRIN M | reporter.nih.gov |
| Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia | NIH | National Cancer Institute | 2025 | $941,798 | August 6, 2025 | July 31, 2030 | CHEN, JIANJUN | reporter.nih.gov |
| Mapping and targeting 3D regulatory elements in leukemia and lymphoma-Supplement | NIH | National Cancer Institute | 2025 | $935,081 | December 13, 2024 | November 30, 2029 | AIFANTIS, IANNIS | reporter.nih.gov |
| Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients | NIH | National Cancer Institute | 2024 to 2025 | $933,644 | May 1, 2024 | April 30, 2029 | KAUFMANN, SCOTT H | reporter.nih.gov |
| Targeting NAMPT in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $932,414 | August 2, 2018 | July 31, 2025 | LAPALOMBELLA, ROSA | reporter.nih.gov |
| Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance | NIH | National Cancer Institute | 2021 to 2023 | $916,031 | May 7, 2019 | April 30, 2024 | SYKES, STEPHEN MATTHEW | reporter.nih.gov |
| Targeting the Notch:Myc axis in leukemia/lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $908,222 | January 1, 2018 | December 31, 2023 | PEAR, WARREN S | reporter.nih.gov |
| Hypertension Intervention to Reduce Osteonecrosis in Children with Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $899,780 | April 1, 2020 | March 31, 2025 | KAROL, SETH EVAN | reporter.nih.gov |
| Role of CXCR3-CXCL10 signaling in T-ALL CNS disease | NIH | National Cancer Institute | 2024 to 2025 | $898,436 | April 1, 2024 | March 31, 2029 | MATLAWSKA-WASOWSKA, KSENIA | reporter.nih.gov |
| Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $897,984 | April 1, 2020 | March 31, 2025 | RAIKAR, SUNIL SUDHIR | reporter.nih.gov |
| Targeting Novel Protein Complexes for the Treatment of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $894,596 | September 1, 2006 | May 31, 2025 | PLATANIAS, LEONIDAS C. | reporter.nih.gov |
| Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $891,269 | December 20, 2019 | March 31, 2022 | KIEM, HANS-PETER | reporter.nih.gov |
| Comprehensive Informatic Analyses of AML Genomes and Epigenomes | NIH | National Cancer Institute | 2021 to 2025 | $882,731 | September 20, 2017 | August 31, 2027 | MILLER, CHRISTOPHER A | reporter.nih.gov |
| NCI Research Specialist (Clinician Scientist) Award | NIH | National Cancer Institute | 2025 | $882,470 | September 1, 2025 | August 31, 2030 | SCHAFER, ERIC STEPHEN | reporter.nih.gov |
| Overcoming Therapy Resistance in Fusion Oncoprotein Driven Pediatric Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $882,356 | August 6, 2024 | July 31, 2029 | WAGENBLAST, ELVIN | reporter.nih.gov |
| The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia | NIH | National Cancer Institute | 2024 to 2025 | $877,852 | June 14, 2024 | May 31, 2029 | SU, RUI | reporter.nih.gov |
| The Role of DLST in Leukemogenesis | NIH | National Cancer Institute | 2021 to 2022 | $871,639 | August 7, 2018 | July 31, 2024 | FENG, HUI | reporter.nih.gov |
| Genomic Expert Curation Panels for Pediatric Malignancies | NIH | National Cancer Institute | 2022 to 2024 | $870,349 | September 22, 2022 | August 31, 2025 | GRIFFITH, OBI L. | reporter.nih.gov |
| Psychobiological stress vulnerability, executive control, and emotion regulation in children and adolescents with cancer | NIH | National Cancer Institute | 2021 to 2024 | $864,844 | April 1, 2020 | March 31, 2025 | COSGROVE, VICTORIA EILEEN | reporter.nih.gov |
| Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia | NIH | National Cancer Institute | 2024 to 2025 | $853,838 | May 3, 2024 | April 30, 2029 | WAGENBLAST, ELVIN | reporter.nih.gov |
| Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $849,360 | April 1, 2020 | March 31, 2027 | NICHOLS, KIM ERIKA | reporter.nih.gov |
| Measuring treatment response and residual disease in leukemia with personalized, sensitive, and quantitative genomic methods | NIH | National Cancer Institute | 2023 to 2025 | $846,728 | July 1, 2020 | April 30, 2026 | MOFFITT, ANDREA | reporter.nih.gov |
| A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | NIH | National Cancer Institute | 2021 to 2022 | $836,805 | July 1, 2018 | August 31, 2025 | SCHALK, AMANDA M | reporter.nih.gov |
| Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML | NIH | National Cancer Institute | 2021 to 2022 | $829,343 | September 1, 2018 | August 31, 2024 | MALEK, SAMI NIMER | reporter.nih.gov |
| Lineage identification and targeted therapeutics in acute leukemia | NIH | National Cancer Institute | 2021 to 2023 | $820,041 | May 1, 2019 | August 25, 2024 | GLASS, JACOB LOWELL | reporter.nih.gov |
| Understanding and predicting relapse in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2023 | $819,280 | July 1, 2013 | May 31, 2024 | RADICH, JERALD PATRICK | reporter.nih.gov |
| MLL Family Histone Methyltransferases in Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $816,991 | June 1, 2018 | May 31, 2024 | ERNST, PATRICIA | reporter.nih.gov |
| BCL11B activation as an approach for enhancing the efficacy of immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $811,046 | February 11, 2021 | January 31, 2026 | PAREKH, CHINTAN | reporter.nih.gov |
| Therapeutic insights through patient derived leukemia xenografts | NIH | National Cancer Institute | 2022 to 2025 | $807,968 | September 15, 2016 | June 30, 2027 | WUNDERLICH, MARK | reporter.nih.gov |
| Probiotics for Prevention of Acute Graft-vs-Host Disease in Children with Cancer | NIH | National Cancer Institute | 2021 to 2022 | $805,562 | September 6, 2016 | July 31, 2024 | LADAS, ELENA J. | reporter.nih.gov |
| Targeting DOT1L for Degradation in MLL-rearranged Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $800,072 | September 25, 2012 | May 31, 2023 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2021 | $800,000 | April 18, 2019 | February 28, 2022 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Understanding the niche of minimal residual disease leukemia cells | NIH | National Cancer Institute | 2021 to 2022 | $797,074 | August 1, 2013 | August 31, 2024 | KIM, YONG-MI | reporter.nih.gov |
| Multi-antigen-specific CAR T cells to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2023 | $789,102 | September 1, 2020 | June 30, 2024 | JAMES, SCOTT E | reporter.nih.gov |
| Kinase-independent mechanism of resistance to FLT3 inhibitors in AML | NIH | National Cancer Institute | 2023 to 2025 | $786,537 | July 1, 2023 | June 30, 2028 | JONES, LAQUITA M | reporter.nih.gov |
| Exploiting the Metabolic Dependencies of Pediatric AML | NIH | National Cancer Institute | 2023 to 2025 | $786,159 | June 7, 2023 | May 31, 2028 | STEVENS, ALEXANDRA | reporter.nih.gov |
| The roles of SOCS5 in T-ALL migration and tissue infiltration | NIH | National Cancer Institute | 2021 to 2023 | $777,426 | July 1, 2019 | June 30, 2024 | MATLAWSKA-WASOWSKA, KSENIA | reporter.nih.gov |
| IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells | NIH | National Cancer Institute | 2024 to 2025 | $775,260 | July 3, 2024 | June 30, 2029 | DEGREGORI, JAMES V | reporter.nih.gov |
| Improving targeted therapy in FLT3-mutated AML | NIH | National Cancer Institute | 2021 to 2024 | $774,414 | July 1, 2020 | December 31, 2025 | SUNG, PAMELA JEANNETTE | reporter.nih.gov |
| Screening for Inhibitors of the Chromatin Reader SGF29 | NIH | National Cancer Institute | 2025 | $768,437 | April 8, 2025 | March 31, 2028 | DESHPANDE, ANIRUDDHA J. | reporter.nih.gov |
| Function and targeting of a stable transcription factor complex in leukemia | NIH | National Cancer Institute | 2021 to 2022 | $767,708 | September 14, 2011 | March 31, 2023 | ROEDER, ROBERT G | reporter.nih.gov |
| The role of the PAFc subunit Cdc73 in normal hematopoiesis and transformation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $765,066 | April 1, 2018 | March 31, 2024 | MUNTEAN, ANDREW GEORGE | reporter.nih.gov |
| Mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia | NIH | National Heart, Lung, and Blood Institute | 2024 | $764,817 | September 17, 2024 | August 31, 2025 | HISADA, YOHEI M | reporter.nih.gov |
| Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML | NIH | National Cancer Institute | 2021 to 2023 | $749,285 | March 1, 2019 | February 28, 2025 | AGARWAL, ANUPRIYA | reporter.nih.gov |
| Mechanisms of translation regulation by N4-acetylcytidine in cancer cells | NIH | National Cancer Institute | 2021 to 2023 | $747,000 | December 1, 2019 | August 31, 2024 | ARANGO, DANIEL | reporter.nih.gov |
| Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | March 3, 2023 | February 28, 2026 | GLYTSOU, CHRISTINA | reporter.nih.gov |
| Improving the activity of CAR T cells for acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $746,886 | July 1, 2023 | June 30, 2028 | KIM, MIRIAM Y | reporter.nih.gov |
| Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma | NIH | National Cancer Institute | 2021 to 2025 | $744,113 | March 5, 2021 | August 31, 2026 | MERINO, AIMEE | reporter.nih.gov |
| Hematopoietic Stem Cell And Cord Blood Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $743,524 | September 30, 2005 | March 31, 2022 | PETERSDORF, EFFIE W | reporter.nih.gov |
| Interrogating oncogene-dependency and mutation order in FLT3 mutant AML | NIH | National Cancer Institute | 2022 to 2024 | $743,326 | September 1, 2022 | August 31, 2025 | BOWMAN, ROBERT LYLE | reporter.nih.gov |
| Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 | $741,625 | April 1, 2023 | August 31, 2023 | BETTS, BRIAN C | reporter.nih.gov |
| Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2025 | $738,698 | March 7, 2025 | February 28, 2030 | WONG, JEFFREY Y | reporter.nih.gov |
| Targeting AMP Synthesis to Overcome Resistance to BH3 Mimetics in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $734,435 | March 10, 2025 | February 28, 2030 | LI, LING | reporter.nih.gov |
| Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $731,472 | April 1, 2017 | March 31, 2024 | ENGEL, MICHAEL E | reporter.nih.gov |
| The pathogenesis of chromosome 7q deletions in juvenile myelomonocytic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $730,258 | September 20, 2018 | August 31, 2024 | MCNERNEY, MEGAN | reporter.nih.gov |
| The role of glutaminolysis as a therapeutic target in T-ALL | NIH | National Cancer Institute | 2021 to 2022 | $727,426 | July 1, 2019 | June 30, 2023 | HERRANZ, DANIEL | reporter.nih.gov |
| Functional and Translational Epigenomics of Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $727,239 | March 1, 2018 | February 28, 2024 | CLEARY, MICHAEL L | reporter.nih.gov |
| The role of adverse social-biological interactions in acute myeloid leukemia disparities | NIH | National Cancer Institute | 2025 | $726,828 | September 1, 2025 | August 31, 2030 | KHAN, IRUM | reporter.nih.gov |
| Crosstalk between leukemic blasts and the BM microenvironment contribute to leukemic transformation | NIH | National Cancer Institute | 2022 to 2023 | $725,739 | March 4, 2022 | March 2, 2023 | DORRANCE, ADRIENNE M. | reporter.nih.gov |
| Dissecting the Roles and Requirements for RBM39 in Acute Myeloid Leukemia and Normal Hematopoiesis | NIH | National Cancer Institute | 2022 to 2024 | $724,902 | July 1, 2022 | June 30, 2025 | LU, SYDNEY X | reporter.nih.gov |
| The role of pyruvate kinase as a therapeutic target in T-ALL | NIH | National Cancer Institute | 2024 to 2025 | $718,276 | January 11, 2024 | December 31, 2028 | HERRANZ, DANIEL | reporter.nih.gov |
| Understanding Ikaros molecular functions for targeted therapies of pre-B ALL | NIH | National Cancer Institute | 2021 to 2022 | $715,716 | July 25, 2018 | June 30, 2023 | SCHJERVEN, HILDE | reporter.nih.gov |
| Mechanisms regulating chimeric antigen receptor T-cell activity in cancer | NIH | National Cancer Institute | 2021 to 2023 | $714,405 | August 1, 2019 | July 31, 2025 | SINGH, NATHAN | reporter.nih.gov |
| Bispecific Antibody Maintenance Therapy after Allogeneic Bone Marrow Transplant | NIH | National Cancer Institute | 2023 to 2025 | $711,147 | July 17, 2023 | June 30, 2028 | WEBSTER, JONATHAN ALLEN | reporter.nih.gov |
| Personalized vaccine for patients with AML | NIH | National Cancer Institute | 2021 to 2022 | $707,845 | December 9, 2016 | May 31, 2024 | AVIGAN, DAVID E. | reporter.nih.gov |
| Biology and Targeting of noncoding RNAs in AML | NIH | National Cancer Institute | 2021 to 2022 | $706,563 | April 1, 2020 | November 15, 2022 | GARZON, RAMIRO | reporter.nih.gov |
| Functional crosstalk between the Fanconi Anemia and ATRX/DAXX histone chaperone pathways | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $703,792 | May 1, 2019 | April 30, 2024 | YONG, JEONGSIK | reporter.nih.gov |
| Anticancer peptide therapeutics | NIH | National Cancer Institute | 2021 to 2022 | $699,769 | August 1, 2017 | November 30, 2023 | WANG, YIN | reporter.nih.gov |
| Biology and Targeting of noncoding RNAs in AML | NIH | National Cancer Institute | 2023 to 2025 | $694,809 | February 24, 2023 | June 30, 2026 | GARZON, RAMIRO | reporter.nih.gov |
| Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers | NIH | National Cancer Institute | 2021 to 2022 | $692,348 | September 20, 2018 | August 31, 2023 | MARIS, JOHN M | reporter.nih.gov |
| Targeting mitochondrial complex I in acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $688,765 | June 14, 2019 | June 30, 2022 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing | NIH | National Cancer Institute | 2023 to 2024 | $687,444 | April 1, 2023 | March 31, 2026 | YEUNG, CECILIA C | reporter.nih.gov |
| Crosstalk between leukemic blasts and the BM microenvironment contribute to leukemic transformation | NIH | National Cancer Institute | 2024 to 2025 | $686,570 | March 4, 2022 | February 28, 2027 | DORRANCE, ADRIENNE M. | reporter.nih.gov |
| Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML | NIH | National Cancer Institute | 2023 to 2025 | $683,699 | August 1, 2023 | July 31, 2028 | WINTERS, AMANDA C | reporter.nih.gov |
| Pharmacodynamically directed targeted therapy for leukemia | NIH | National Cancer Institute | 2025 | $683,472 | May 1, 2025 | April 30, 2030 | BYRD, JOHN C. | reporter.nih.gov |
| Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL | NIH | National Cancer Institute | 2021 | $682,392 | September 17, 2018 | August 31, 2022 | COLE, PETER D. | reporter.nih.gov |
| Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2 | NIH | National Cancer Institute | 2025 | $678,101 | March 7, 2025 | February 28, 2030 | WIITA, ARUN P. | reporter.nih.gov |
| RIP1/RIP3-Calpain-Stat3 and NF-kappa B pathways in AML pathogenesis and treatment | NIH | National Cancer Institute | 2021 to 2022 | $672,267 | May 1, 2018 | April 30, 2024 | ZHANG, JIWANG | reporter.nih.gov |
| Design of an integrated microdevice to measure malignant lipid signaling in single cells from clinical samples | NIH | National Cancer Institute | 2025 | $671,072 | April 1, 2025 | March 31, 2030 | ALLBRITTON, NANCY L. | reporter.nih.gov |
| Dissecting the role of clonal evolution in NPM1-mutant AML | NIH | National Cancer Institute | 2022 to 2024 | $668,611 | August 15, 2022 | July 31, 2025 | MILES, LINDE A | reporter.nih.gov |
| Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL | NIH | National Cancer Institute | 2022 | $666,287 | September 17, 2018 | August 31, 2024 | COLE, PETER D. | reporter.nih.gov |
| Dysregulated epigenetic control in leukemogenesis | NIH | National Cancer Institute | 2025 | $662,938 | December 10, 2024 | November 30, 2029 | LIU, YAN | reporter.nih.gov |
| COMPRENDO: Adaptation and Implementation of a Peer-Navigation Intervention to Improve Research Literacy and Diversity in Pediatric Leukemia Clinical Trials | NIH | National Cancer Institute | 2021 to 2023 | $658,256 | July 17, 2018 | June 30, 2024 | ARISTIZABAL, PAULA | reporter.nih.gov |
| Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $654,837 | September 22, 2025 | June 30, 2030 | WANG, LI LILY | reporter.nih.gov |
| Dissecting the Mechanism of Acute Myeloid Leukemia Induced Bone Marrow Failure to Identify Therapeutic Interventions | NIH | National Cancer Institute | 2021 to 2024 | $653,996 | June 1, 2020 | May 31, 2025 | ZHANG, TIAN YI | reporter.nih.gov |
| The AYA Oncology Self-Care Movement (#AYAOSM): An Influencer-Driven Social Media Intervention for Oral Chemotherapy Adherence | NIH | National Cancer Institute | 2025 | $651,859 | September 19, 2025 | August 31, 2030 | PSIHOGIOS, ALEXANDRA | reporter.nih.gov |
| Tumor suppressor roles of TFEB in the development and maintenance of myeloid leukemia | NIH | National Cancer Institute | 2021 to 2023 | $650,375 | September 11, 2019 | August 31, 2024 | YUN, SEONGSEOK | reporter.nih.gov |
| Epigenetics of Mutation-Order in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $649,804 | April 1, 2020 | March 31, 2025 | BRAUN, THEODORE PAUL | reporter.nih.gov |
| Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias | NIH | National Cancer Institute | 2021 | $648,759 | June 8, 2017 | May 31, 2023 | JIN, JIAN | reporter.nih.gov |
| Small-molecule MDM2 degraders | NIH | National Cancer Institute | 2021 | $647,004 | August 1, 2017 | July 31, 2024 | WANG, SHAOMENG | reporter.nih.gov |
| Overcoming resistance to menin patient mutations in leukemia | NIH | National Cancer Institute | 2025 | $640,135 | August 1, 2025 | July 31, 2030 | GREMBECKA, JOLANTA | reporter.nih.gov |
| A Healthy Weight Intervention for Family Stress during the Early Phases of ALL Treatment: NOURISH-ALL | NIH | National Cancer Institute | 2023 to 2025 | $623,586 | September 15, 2023 | August 31, 2028 | BATES, CAROLYN R | reporter.nih.gov |
| Enhancing treatments for myeloid leukemia associated with Down syndrome | NIH | National Cancer Institute | 2024 to 2025 | $620,749 | August 1, 2024 | July 31, 2028 | TAUB, JEFFREY WARREN | reporter.nih.gov |
| Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2024 | $618,228 | August 17, 2022 | July 31, 2027 | MILLMAN, SCOTT EVAN | reporter.nih.gov |
| Understanding mechanisms of impaired immunity in the AML bone marrow | NIH | National Cancer Institute | 2024 to 2025 | $607,242 | July 1, 2024 | June 30, 2029 | DEWOLF, SUSAN E | reporter.nih.gov |
| Opioid-induced changes to chemotherapeutic activity in blood cancer | NIH | National Cancer Institute | 2022 to 2024 | $600,939 | August 1, 2022 | July 31, 2025 | CONSTANCE, JONATHAN ERIC | reporter.nih.gov |
| Hematopoietic consequences of gain-of-function SAMD9 and SAMD9L mutations | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $594,864 | November 1, 2020 | January 31, 2025 | SCHWARTZ, JASON ROSS | reporter.nih.gov |
| Instructive role of MLL fusion proteins in lineage determination and leukemogenesis | NIH | National Cancer Institute | 2021 | $594,545 | March 1, 2017 | February 28, 2023 | THIRMAN, MICHAEL J | reporter.nih.gov |
| Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | NIH | National Cancer Institute | 2024 to 2025 | $591,241 | August 24, 2021 | July 31, 2026 | KNOECHEL, BIRGIT | reporter.nih.gov |
| Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL) | NIH | National Cancer Institute | 2024 to 2025 | $578,916 | September 1, 2024 | August 31, 2029 | TALLEUR, AIMEE C. | reporter.nih.gov |
| Computational Approaches for Studying Transcription Elongation Control in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $577,568 | September 5, 2022 | August 31, 2027 | IWANASZKO, MARTA | reporter.nih.gov |
| Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen | NIH | National Cancer Institute | 2022 to 2024 | $568,214 | June 17, 2019 | May 31, 2025 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Joint differentiation-state plasticity and genetic diversity modeling to predict response and improve efficacy of drug combination therapy | NIH | National Cancer Institute | 2022 to 2024 | $566,323 | May 10, 2022 | May 31, 2025 | NIKOLOVA, OLGA H | reporter.nih.gov |
| Dissecting the Functional Role of Monocytes in B-cell Acute Lymphoblastic Leukemia Survival | NIH | National Cancer Institute | 2022 to 2024 | $553,368 | May 12, 2022 | March 31, 2025 | WITKOWSKI, MATTHEW | reporter.nih.gov |
| CD25-mediated feedback control of BCR-signaling and its oncogenic mimics | NIH | National Cancer Institute | 2021 to 2022 | $549,899 | January 1, 2021 | May 31, 2023 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Regulation of cardiac metabolism during Leukemia | NIH | National Heart, Lung, and Blood Institute | 2025 | $549,796 | March 1, 2025 | December 31, 2029 | KARLSTAEDT, ANJA | reporter.nih.gov |
| Therapeutic targeting of an oncogenic translational program in AML | NIH | National Cancer Institute | 2025 | $545,170 | April 1, 2025 | March 31, 2030 | PULIKKAN, JOHN | reporter.nih.gov |
| Role of targeting ATPases BRG1/BRM in therapy of AML | NIH | National Cancer Institute | 2025 | $542,663 | April 11, 2025 | March 31, 2030 | FISKUS, WARREN CAMPBELL | reporter.nih.gov |
| Prognostic implications of mitochondrial inheritance in myelodysplastic syndromes after stem-cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $540,539 | April 20, 2023 | March 31, 2028 | DONG, JING | reporter.nih.gov |
| The role of catecholamines in immunotoxicity and tumor response of adoptive T cell therapy in cancer | NIH | National Cancer Institute | 2021 to 2022 | $540,384 | July 1, 2018 | June 30, 2023 | STAEDTKE, VERENA | reporter.nih.gov |
| Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy | NIH | National Cancer Institute | 2023 to 2025 | $539,966 | March 1, 2023 | February 29, 2028 | MYERS, REGINA M | reporter.nih.gov |
| Cheminformatics-based identification of leukemia-targeting molecules | NIH | National Cancer Institute | 2024 to 2025 | $536,817 | April 1, 2024 | March 31, 2027 | KIRIENKO, NATASHA | reporter.nih.gov |
| Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells | NIH | National Cancer Institute | 2025 | $530,106 | September 11, 2025 | August 31, 2030 | JONES, COURTNEY LYNN | reporter.nih.gov |
| Clinical Trials Specialist in Developmental Therapeutics | NIH | National Cancer Institute | 2023 to 2025 | $527,832 | September 5, 2023 | August 31, 2028 | HIJIYA, NOBUKO | reporter.nih.gov |
| The Role and Function of a Novel Signature Gene in BCR::ABL1 (Ph) B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $517,090 | August 18, 2025 | July 31, 2030 | GU, ZHAOHUI | reporter.nih.gov |
| Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $511,882 | December 10, 2018 | March 31, 2022 | PAGUIRIGAN, AMY | reporter.nih.gov |
| Development of a novel survey to screen for chemotherapy-induced peripheral neuropathy in young children | NIH | National Cancer Institute | 2024 to 2025 | $511,478 | September 1, 2024 | August 31, 2029 | RODWIN, ROZALYN | reporter.nih.gov |
| Targeting Leukemia Stem Cells with Small Molecule Heat Shock Transcription Factor 1 Degrader | NIH | National Cancer Institute | 2025 | $502,516 | April 1, 2025 | March 31, 2030 | ZHAO, CHEN | reporter.nih.gov |
| Repeat enhancers as drivers of ETV6-RUNX1+ and ETV6-RUNX1-like B-lymphoblastic leukemia | NIH | National Cancer Institute | 2025 | $500,719 | March 1, 2025 | February 28, 2030 | RYAN, RUSSELL JAMES HUBBARD | reporter.nih.gov |
| FAACS: Feasibility/Acceptability of Attentional-Control Training in Survivors | NIH | National Cancer Institute | 2022 to 2023 | $500,098 | September 1, 2022 | August 31, 2025 | HARDY, STEVEN JAMES | reporter.nih.gov |
| Logic Gated Precision Molecular Adaptor System for Juvenile Myelomonocytic Leukemia Treatment | NIH | National Cancer Institute | 2025 | $499,990 | September 12, 2025 | September 11, 2026 | reporter.nih.gov | |
| Characterization of novel subtypes in B progenitor acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $498,000 | July 13, 2020 | June 30, 2023 | GU, ZHAOHUI | reporter.nih.gov |
| Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia | NIH | National Cancer Institute | 2024 to 2025 | $497,962 | April 1, 2024 | March 31, 2027 | LIN, SHAN | reporter.nih.gov |
| Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML | NIH | National Cancer Institute | 2025 | $495,715 | August 5, 2025 | July 31, 2030 | XIAO, WENBIN | reporter.nih.gov |
| Creating a transient metabolic catastrophe for AML therapy | NIH | National Cancer Institute | 2025 | $491,357 | March 15, 2025 | February 28, 2030 | TIROSH, BOAZ | reporter.nih.gov |
| Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $490,583 | August 1, 2023 | July 31, 2025 | PERNA, FABIANA | reporter.nih.gov |
| The cohesin complex as a tumor suppressor in myeloid leukemia | NIH | National Cancer Institute | 2021 | $488,648 | June 1, 2017 | May 31, 2022 | AIFANTIS, IANNIS | reporter.nih.gov |
| Pre-Leukemic Hematopoietic Stem Cells in Human AML | NIH | National Cancer Institute | 2025 | $487,973 | January 1, 2025 | December 31, 2029 | MAJETI, RAVINDRA | reporter.nih.gov |
| Targeting mitochondrial RNA methylation in high-risk acute myeloid leukemia | NIH | National Cancer Institute | 2025 | $487,542 | December 10, 2024 | November 30, 2029 | SU, RUI | reporter.nih.gov |
| Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders | NIH | National Cancer Institute | 2023 to 2025 | $485,634 | August 15, 2023 | July 31, 2028 | LASZLO, GEORGE S | reporter.nih.gov |
| Investigating and targeting NSD2 mutation-driven leukemia transformation | NIH | National Cancer Institute | 2025 | $484,405 | September 1, 2025 | August 31, 2030 | LI, JIANPING | reporter.nih.gov |
| Assessment of DCAF15 role in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $483,760 | April 1, 2025 | March 31, 2030 | BUSINO, LUCA | reporter.nih.gov |
| Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $483,110 | September 1, 2025 | August 31, 2030 | GU, ZHAOHUI | reporter.nih.gov |
| Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $481,818 | January 20, 2025 | December 31, 2029 | WITKOWSKI, MATTHEW | reporter.nih.gov |
| BMT Core - Oregon Health and Science University (OHSU) Consortium | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $472,000 | August 15, 2024 | June 30, 2031 | MAZIARZ, RICHARD THOMAS | reporter.nih.gov |
| Targeting FOXM1 in chemo-resistant monocytic AML | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $471,119 | July 1, 2021 | April 30, 2024 | GARTEL, ANDREI L | reporter.nih.gov |
| Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen | NIH | National Cancer Institute | 2021 to 2022 | $470,748 | June 17, 2019 | June 30, 2022 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Modeling and Targeting B/Myeloid Mixed Phenotype Acute Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $462,952 | March 3, 2022 | February 29, 2024 | CHEN, WENYONG | reporter.nih.gov |
| Characterizing DNA Methylation Dynamics in Trisomy 21-Associated Hematopoiesis and Leukemia | NIH | National Cancer Institute | 2025 | $462,454 | August 8, 2025 | June 30, 2027 | MA, SAI | reporter.nih.gov |
| 3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors | NIH | National Cancer Institute | 2025 | $461,983 | May 10, 2022 | April 30, 2027 | SINTIM, HERMAN O | reporter.nih.gov |
| Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $459,226 | August 22, 2011 | June 30, 2024 | BASHEY, ASAD | reporter.nih.gov |
| Genes regulating stem and progenitor cell expansion and relapse in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $458,698 | March 10, 2025 | February 28, 2030 | MALEK, SAMI NIMER | reporter.nih.gov |
| Uncovering therapeutic vulnerabilities in AML through mechanistic interrogation of MECOM activity | NIH | National Cancer Institute | 2024 to 2025 | $457,958 | July 1, 2024 | June 30, 2029 | VOIT, RICHARD A | reporter.nih.gov |
| Targeting TET1 signaling to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $457,310 | January 1, 2017 | December 31, 2021 | CHEN, JIANJUN | reporter.nih.gov |
| Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy | NIH | National Cancer Institute | 2021 to 2023 | $456,685 | September 19, 2019 | February 28, 2025 | GREENZANG, KATIE A. | reporter.nih.gov |
| CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome | NIH | National Cancer Institute | 2022 to 2023 | $455,366 | August 1, 2022 | July 31, 2025 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | NIH | National Cancer Institute | 2022 | $455,000 | April 1, 2022 | March 31, 2023 | FEDERATION, ALEXANDER | reporter.nih.gov |
| Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies | NIH | National Cancer Institute | 2023 to 2024 | $453,040 | April 1, 2024 | June 30, 2024 | ZHOU, XIANZHENG | reporter.nih.gov |
| The Role of DDX41 in Inherited Myelodysplastic Syndromes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $451,332 | September 1, 2019 | July 31, 2024 | CHLON, TIMOTHY MICHAEL | reporter.nih.gov |
| Chemical manipulation of creatine kinases to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $450,655 | April 1, 2021 | September 30, 2023 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Targeting the PD-1H (VISTA) Pathway to Overcome Immunosuppression in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $449,222 | August 20, 2025 | July 31, 2030 | HAN, XUE | reporter.nih.gov |
| Utilizing Hybrid Antigen-Presenting Neutrophils to Prime WT1-Specific Immune Responses as Therapy for Acute Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $448,427 | December 1, 2021 | November 30, 2024 | MANUEL, EDWIN | reporter.nih.gov |
| Methotrexate effects on synaptic plasticity: a path to female resiliency to chemotherapy-induced cognitive deficits | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $445,500 | May 15, 2025 | April 30, 2027 | REYES, TERESA M | reporter.nih.gov |
| Role of perinatal testosterone in programming behavioral and astrocyte responses to early life chemotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $445,500 | August 1, 2025 | July 31, 2027 | REYES, TERESA M | reporter.nih.gov |
| The Role of CHAF1B in Maintaining Malignant Leukemia Stem Cells | NIH | National Cancer Institute | 2021 to 2022 | $444,213 | June 1, 2020 | May 31, 2023 | VOLK, ANDREW | reporter.nih.gov |
| Leukemia stem cell polarity and differentiation therapy | NIH | National Cancer Institute | 2021 | $442,805 | September 1, 2017 | July 31, 2022 | MULLOY, JAMES C | reporter.nih.gov |
| Mitochondrial Dysfunction underlies treatment related hepatotoxicity in Hispanics with acute lymphoblastic leukemia | NIH | National Cancer Institute | 2023 | $442,404 | September 14, 2023 | August 31, 2025 | ALACHKAR, HOUDA | reporter.nih.gov |
| Functional Interrogation of Human Acute Myeloid Leukemia Stem Cells | NIH | National Cancer Institute | 2025 | $439,644 | December 1, 2024 | November 30, 2029 | MAJETI, RAVINDRA | reporter.nih.gov |
| Oncogenic impact of eIF4E-dependent RNA export in cancer | NIH | National Cancer Institute | 2023 to 2024 | $435,689 | April 1, 1999 | October 11, 2024 | BORDEN, KATHERINE L B | reporter.nih.gov |
| Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $435,520 | December 1, 2021 | March 31, 2023 | XU, JIAN | reporter.nih.gov |
| Developing Multispecific T cell Engaging Therapy for Mixed Phenotype Acute Leukemia | NIH | National Cancer Institute | 2025 | $434,361 | September 1, 2025 | August 31, 2027 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 | $430,377 | February 16, 2017 | December 31, 2022 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | NIH | National Cancer Institute | 2024 to 2025 | $430,358 | April 1, 2024 | February 28, 2029 | HEIKAMP, EMILY | reporter.nih.gov |
| Development of inhibitors to selectively target the CBX8 chromatin reader domain | NIH | National Cancer Institute | 2025 | $429,123 | April 1, 2025 | March 31, 2030 | DYKHUIZEN, EMILY CARLA | reporter.nih.gov |
| Engineering Natural Killer Cells to Target Acute Myeloid Leukemia with HLA-DR Loss | NIH | National Cancer Institute | 2025 | $429,000 | July 1, 2025 | June 30, 2028 | XIE, JIANMING | reporter.nih.gov |
| High-efficiency microfluidic cell fusion for dendritic cell/tumor cell vaccine production | NIH | National Cancer Institute | 2021 | $428,524 | April 2, 2021 | April 30, 2024 | VOLDMAN, JOEL | reporter.nih.gov |
| Mechanisms of inv(16) acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $426,803 | December 6, 2016 | November 30, 2022 | CASTILLA, LUCIO H. | reporter.nih.gov |
| The role and mechanism of FTO in leukemogenesis and drug response | NIH | National Cancer Institute | 2021 | $426,319 | April 1, 2017 | March 31, 2022 | CHEN, JIANJUN | reporter.nih.gov |
| Targeting FL3 and SRC kinases for AML therapy | NIH | National Cancer Institute | 2023 to 2024 | $424,665 | April 1, 2023 | March 31, 2026 | REDDY, E PREMKUMAR | reporter.nih.gov |
| Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery | NIH | National Cancer Institute | 2021 to 2022 | $424,307 | July 1, 2021 | June 30, 2023 | WIITA, ARUN P. | reporter.nih.gov |
| Adipose Tissue Reprograms Acute Lymphoblastic Leukemia Cells to Facilitate CNS and Bone Invasion | NIH | National Cancer Institute | 2024 to 2025 | $422,076 | April 1, 2024 | March 31, 2026 | MITTELMAN, STEVEN DAVID | reporter.nih.gov |
| Mechanisms of caspase-2 activation by nucleophosmin in AML cell death and survival | NIH | National Cancer Institute | 2021 to 2022 | $421,941 | January 15, 2021 | June 30, 2023 | BOUCHIER-HAYES, LISA | reporter.nih.gov |
| Oncogenic Impact of eIF4E-dependent RNA Export in Cancer | NIH | National Cancer Institute | 2024 to 2025 | $420,588 | April 1, 1999 | February 28, 2028 | BORDEN, KATHERINE L B | reporter.nih.gov |
| Cassette exons in neoplastic pro-B-cells: implications for immunotherapy | NIH | National Cancer Institute | 2022 | $420,362 | September 14, 2018 | June 30, 2024 | THOMAS-TIKHONENKO, ANDREI | reporter.nih.gov |
| Causal machine learning methods for studying the effects of environmental exposures on childhood cancer using natural experiments | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $416,694 | February 1, 2021 | January 31, 2025 | NETHERY, RACHEL C | reporter.nih.gov |
| The role of long noncoding RNAs in acute myeloid leukemia | NIH | National Cancer Institute | 2024 | $415,259 | August 1, 2024 | July 31, 2026 | TRINH, BON Q | reporter.nih.gov |
| Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML) | NIH | National Cancer Institute | 2023 to 2024 | $415,216 | December 8, 2022 | November 30, 2025 | WANG, VICTORIA | reporter.nih.gov |
| Novel drug to treat poor prognosis AML | NIH | National Cancer Institute | 2021 to 2022 | $414,921 | July 2, 2021 | June 30, 2023 | KAPUR, REUBEN | reporter.nih.gov |
| Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML | NIH | National Cancer Institute | 2022 to 2023 | $412,757 | May 20, 2022 | March 31, 2024 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2024 | $412,685 | July 1, 2024 | June 30, 2026 | LACORAZZA, DANIEL | reporter.nih.gov |
| Human Donor Stem/Progenitor Cells with Dual Gene Editing (CD33 and CLL-1) Enable "Two Hit" targeting of Acute Myeloid Leukemia" | NIH | National Cancer Institute | 2021 to 2022 | $411,999 | December 3, 2020 | November 30, 2022 | ALI, ABDULLAH M | reporter.nih.gov |
| Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML | NIH | National Cancer Institute | 2022 to 2023 | $411,999 | January 13, 2022 | December 31, 2024 | ANDREEFF, MICHAEL | reporter.nih.gov |
| NCI Research Specialist (Clinician Scientist) Award | NIH | National Cancer Institute | 2023 to 2025 | $411,489 | April 1, 2023 | March 31, 2028 | FOSTER, JENNIFER HAUNANI | reporter.nih.gov |
| Targeting defective spliceosomal pathway in myeloid malignancies | NIH | National Cancer Institute | 2022 to 2023 | $410,690 | April 1, 2022 | March 31, 2025 | YANG, CHAO-YIE | reporter.nih.gov |
| Sequestration and deactivation of anthracycline by adipocytes in the leukemia microenvironment | NIH | National Cancer Institute | 2021 | $410,198 | August 15, 2017 | July 31, 2023 | MITTELMAN, STEVEN DAVID | reporter.nih.gov |
| Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia | NIH | National Cancer Institute | 2025 | $409,732 | September 12, 2025 | August 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $409,455 | August 1, 2021 | July 31, 2024 | SIPKINS, DOROTHY A | reporter.nih.gov |
| Infectious pressures on cell competition and cooperation during leukemia initiation | NIH | National Cancer Institute | 2021 | $408,829 | May 1, 2021 | April 30, 2023 | GRIMES, H. LEIGHTON | reporter.nih.gov |
| Characterization of native AMPA receptor structure and function in glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $408,501 | March 1, 2022 | February 28, 2026 | SPANGLER, CATHERINE JEANETTE | reporter.nih.gov |
| A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma | NIH | National Cancer Institute | 2023 to 2024 | $408,498 | July 7, 2023 | June 30, 2025 | WINTER, STUART SHELDON | reporter.nih.gov |
| Enhancing CAR T Cell Homing Through Glycoengineering | NIH | National Cancer Institute | 2023 to 2024 | $407,075 | March 9, 2023 | February 28, 2026 | AL-ATRASH, GHEATH | reporter.nih.gov |
| Dual anti-leukemic and cardio protective role for ROCK | NIH | National Cancer Institute | 2022 to 2023 | $403,839 | April 1, 2022 | March 31, 2024 | KAPUR, REUBEN | reporter.nih.gov |
| Expression of High-Activity and High-SpecificityMicrobial L-Asparaginases from Naturally Occurring Microorganisms in the Alabama Black Belt | NIH | National Institute of General Medical Sciences | 2025 | $403,640 | September 5, 2025 | August 31, 2028 | OKEKE, BENEDICT C | reporter.nih.gov |
| Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia | NIH | National Cancer Institute | 2025 | $402,600 | April 3, 2025 | March 31, 2030 | DANIYAN, ANTHONY FOLAWUYI | reporter.nih.gov |
| Targeting AML Mitochondria by Ceramide | NIH | National Cancer Institute | 2022 | $400,000 | September 1, 2022 | August 31, 2024 | OGRETMEN, BESIM | reporter.nih.gov |
| Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy | NIH | National Cancer Institute | 2024 | $400,000 | August 1, 2024 | July 31, 2026 | SCHALK, AMANDA M | reporter.nih.gov |
| Development of a novel pan-cancer CAR-T product against AML and Glioblastoma | NIH | National Cancer Institute | 2024 | $400,000 | September 16, 2024 | August 31, 2025 | SOLER, DAVID | reporter.nih.gov |
| Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $399,998 | August 7, 2025 | July 31, 2026 | CHEN, THOMAS C. | reporter.nih.gov |
| Novel Sequencing Based Diagnostics for Leukemia in Low Resource Settings | NIH | National Cancer Institute | 2022 to 2023 | $399,830 | July 1, 2022 | June 30, 2025 | ALEXANDER, THOMAS BLICK | reporter.nih.gov |
| Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies | NIH | National Cancer Institute | 2025 | $399,739 | September 10, 2025 | August 31, 2027 | ELSER, JEREMY A | reporter.nih.gov |
| Mechanisms of Formation and Progression of Preleukemic Stem Cells | NIH | National Cancer Institute | 2021 | $397,371 | April 1, 2017 | March 31, 2022 | STEIDL, ULRICH | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Public Health Institute | Oakland, CA | 3 | $157.8 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 35 | $45.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 10 | $40.8 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 25 | $34.9 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 22 | $28.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 7 | $26.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 23 | $25.8 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 13 | $20.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 14 | $20 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 18 | $19.7 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 17 | $19.1 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 20 | $18 million | 0 | $0 |
| Washington University | Saint Louis, MO | 18 | $17.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 12 | $17.1 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 21 | $15.9 million | 0 | $0 |
| Yale University | New Haven, CT | 10 | $15 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 14 | $14.4 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 14 | $14.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 11 | $14 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 13 | $13.4 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 14 | $12.1 million | 0 | $0 |
| Ohio State University | Columbus, OH | 12 | $11.7 million | 0 | $0 |
| HudsonAlpha Institute for Biotechnology | Huntsville, AL | 1 | $11.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 17 | $11 million | 0 | $0 |
| University of Florida | Gainesville, FL | 7 | $10.7 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 5 | $10.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 13 | $10.2 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 9 | $8.3 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 10 | $8 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 5 | $7.8 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 12 | $7.4 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 6 | $7.3 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 5 | $7 million | 0 | $0 |
| Children's Hospital of Los Angeles | Los Angeles, CA | 4 | $6.8 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 4 | $6.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 7 | $6.8 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 5 | $6.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $6.4 million | 0 | $0 |
| Versiti Blood Health, Inc. | Milwaukee, WI | 6 | $6.2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 4 | $5.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 5 | $5.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 7 | $5.6 million | 0 | $0 |
| Emory University | Atlanta, GA | 10 | $5.6 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 7 | $5.3 million | 0 | $0 |
| Duke University | Durham, NC | 6 | $5.3 million | 0 | $0 |
| Cold Spring Harbor Laboratory | Cold Spring Harbor, NY | 4 | $5.2 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 3 | $4.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 9 | $4.8 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 5 | $4.7 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 5 | $4 million | 0 | $0 |
| Twinstrand Biosciences, Inc. | Seattle, WA | 1 | $4 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 5 | $3.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 5 | $3.7 million | 0 | $0 |
| University College London | London | 1 | $3.6 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 3 | $3.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 7 | $3.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 8 | $3.2 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 2 | $3.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 4 | $3.1 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 3 | $3.1 million | 0 | $0 |
| New York University | New York, NY | 2 | $3.1 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 7 | $2.9 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 2 | $2.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 2 | $2.6 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 4 | $2.6 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 1 | $2.6 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 2 | $2.5 million | 0 | $0 |
| University of New South Wales | Sydney | 1 | $2.5 million | 0 | $0 |
| Talus Bioscience, Inc. | Seattle, WA | 2 | $2.5 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 3 | $2.4 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 2 | $2.4 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 1 | $2.2 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 2 | $2.2 million | 0 | $0 |
| Loma Linda University | Loma Linda, CA | 2 | $2.1 million | 0 | $0 |
| Fannin Partners, LLC | Houston, TX | 1 | $2.1 million | 0 | $0 |
| University of Rochester | Rochester, NY | 3 | $2.1 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 1 | $2.1 million | 0 | $0 |
| Arkansas Children's Hospital Res Inst | Little Rock, AR | 1 | $2.1 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $2 million | 0 | $0 |
| Coriell Institute for Medical Research | Camden, NJ | 1 | $2 million | 0 | $0 |
| Phase Genomics, Inc. | Seattle, WA | 1 | $2 million | 0 | $0 |
| Senti Biosciences, Inc. | South San Francisco, CA | 1 | $2 million | 0 | $0 |
| March Biosciences INC | Houston, TX | 1 | $2 million | 0 | $0 |
| Keystone Nano, Inc. | State College, PA | 1 | $2 million | 0 | $0 |
| Marker Therapeutics, Inc. | Houston, TX | 1 | $2 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $1.9 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 2 | $1.8 million | 0 | $0 |
| Florida International University | Miami, FL | 1 | $1.8 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 3 | $1.8 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 2 | $1.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 3 | $1.7 million | 0 | $0 |
| Actinium Pharmaceuticals, Inc. | New York, NY | 1 | $1.7 million | 0 | $0 |
| Pacific Northwest Research Institute | Seattle, WA | 1 | $1.6 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 2 | $1.6 million | 0 | $0 |
| Northwestern University | Chicago, IL | 2 | $1.4 million | 0 | $0 |
| RBHS -Cancer Institute of New Jersey | New Brunswick, NJ | 2 | $1.4 million | 0 | $0 |
| Cambium Oncology LLC | Atlanta, GA | 1 | $1.4 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 1 | $1.4 million | 0 | $0 |
| Battelle Pacific Northwest Laboratories | Richland, WA | 1 | $1.4 million | 0 | $0 |
| Augusta University | Augusta, GA | 1 | $1.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 332 | $200,053,481 | 0 | $0 |
| 2024 | 368 | $197,568,154 | 0 | $0 |
| 2023 | 373 | $192,650,287 | 0 | $0 |
| 2022 | 371 | $178,202,565 | 0 | $0 |
| 2021 | 339 | $180,702,790 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.